Key targets include the epidermal growth factor receptor (EGFR), which is often amplified or mutated in glioblastoma, and phosphatidylinositol 3-kinase (PI3K)/Akt/mTOR pathways, critical for cell proliferation and survival. This evidence concerns the gene EGFR and glioblastoma.